Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Revenue (2021 - 2024)

Goldenwell Biotech filings provide 4 years of Revenue readings, the most recent being -$158.0 for Q4 2024.

  • On a quarterly basis, Revenue fell 160.77% to -$158.0 in Q4 2024 year-over-year; TTM through Sep 2025 was -$158.0, a 139.6% decrease, with the full-year FY2024 number at $139.0, down 92.43% from a year prior.
  • Revenue hit -$158.0 in Q4 2024 for Goldenwell Biotech, down from $139.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $43690.0 in Q3 2022 to a low of -$158.0 in Q4 2024.
  • Median Revenue over the past 4 years was $751.5 (2021), compared with a mean of $5691.7.
  • Biggest five-year swings in Revenue: soared 259.12% in 2022 and later tumbled 160.77% in 2024.
  • Goldenwell Biotech's Revenue stood at $4907.0 in 2021, then skyrocketed by 790.36% to $43690.0 in 2022, then crashed by 99.4% to $260.0 in 2023, then tumbled by 160.77% to -$158.0 in 2024.
  • The last three reported values for Revenue were -$158.0 (Q4 2024), $139.0 (Q2 2024), and $260.0 (Q4 2023) per Business Quant data.